Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has led the largest and most comprehensive analysis of the entire genomic landscape of the commonest type of blood cancer called chronic lymphocytic leukaemia (CLL) as part of the UK’s 100,000 Genomes Project. This work defines five genomic subgroups of CLL and associates these with clinical outcomes, and these subgroups provide a better estimation of patient prognosis than achieved by previous single gene analyses, allowing more tailored patient care.

digital illustration of a human DNA strand

A collaborative study led by the University of Oxford as part of the UK’s 100,000 Genomes Project, published in Nature Genetics, has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukaemia (CLL) and associated these with clinical outcomes. This new method for risk stratifying patients could lead to more personalised patient care.

This is the first study to analyse all the relevant changes in DNA across the entire cancer genome, rather than targeted regions, to classify patients with cancer and link these subgroups to clinical outcomes.

Professor Anna Schuh of Oxford's Department of Oncology, who led the study, said: ‘We know that cancer is fundamentally a disease caused by changes in DNA that are acquired over the lifetime of an individual. The lab tools we currently use to predict whether or not a patient is likely to respond to a given therapy usually focus on single abnormalities in the cancer DNA and do not accurately predict the patient’s clinical outcome. This is why we asked the simple question: can we increase the precision of current testing by looking at all the acquired DNA changes in cancer at once?’

Read the full story on the Oxford Cancer website